Another study demonstrated that the competitive blocking of HVEM to BTLA but not to LIGHT suppresses immune rejection in a murine GvHR model, indicating that effective CD4 and CD8 T-cell responses rely on HVEM/BTLA signaling and that the HVEM/BTLA pathway could present a new therapeutic target in autoimmune diseases [49]. This evidence concerns the gene TNFSF14 and autoimmune disease.